Ascending paralysis: causes and immediate action

"Ascending nerve palsy" is the historical name for an acute immune-mediated peripheral nerve injury in which weakness begins in the feet and legs and "ascends" up the extremities. This syndrome is now called "Guillain-Barré syndrome." It encompasses several clinical and electrophysiological variants, ranging from demyelinating to axonal, as well as a "periocular" form called Miller-Fisher syndrome. This acute condition most often develops 1-4 weeks after infection and can progress to respiratory failure. [1]

Guillain-Barré syndrome is an autoimmune attack against peripheral nerve components—myelin or axolemma. Some patients have antibodies to gangliosides (e.g., GM1 or GQ1b), which explains the clinical phenotypes: motor axonal forms are more often associated with antibodies to GM1, and Miller-Fisher syndrome with antibodies to GQ1b. Molecular mimicry between bacterial lipooligosaccharides (e.g., Campylobacter jejuni) and human nerve gangliosides is a key mechanism. [2]

Despite the potential severity of the disease, the outcome is favorable in most cases with timely diagnosis and treatment: approximately 70-80% of patients are able to walk without support within 6 months, although some experience persistent pain, fatigue, and sensory impairment. Meanwhile, 20-30% require mechanical ventilation at the peak of the disease, and autonomic dysfunction occurs in approximately half of patients and can be life-threatening. [3]

Below is a complete, modern, clinically-oriented "roadmap": from classification codes and epidemiology to diagnosis, treatment, and rehabilitation, with step-by-step explanations and tables.

Nomenclature and codes according to international classifications

Historically, "ascending paralysis" corresponded to Landry's description. Today, the correct nomenclature is "Guillain-Barré syndrome," which includes the acute inflammatory demyelinating polyradiculoneuropathic variant and axonal variants (acute motor axonal neuropathy, acute motor-sensory axonal neuropathy), as well as Miller-Fisher syndrome and related forms. This unification reflects a common immunopathogenetic nature with phenotypic diversity. [4]

The International Classification of Diseases, Tenth Revision, uses the code G61.0 for Guillain-Barré syndrome. The International Classification of Diseases, Eleventh Revision uses the base code 8C01.0 "Acute inflammatory demyelinating polyneuropathy," under which synonyms and inclusions are listed (including "acute ascending Landry palsy," motor axonal variants). This is important for medical documentation, epidemiology, and patient routing between services. [5]

Linking the correct nomenclature to codes facilitates work with registries, insurance claims, and outcome statistics. In research practice, this also helps stratify patients by subtype and prognosis, which is critical when interpreting treatment effectiveness and planning clinical trials. [6]

The term "ascending paralysis" is acceptable as a historical and descriptive term, but in the clinic it is preferable to use modern terms and codes to maintain consistency with guidelines and standards of care. [7]

Table 1. Codes and correspondences

Classification	Code	Name	Notes/Inclusions
ICD-10	G61.0	Guillain-Barre syndrome	Includes "acute ascending paralysis"
ICD-11	8C01.0	Acute inflammatory demyelinating polyneuropathy	Synonyms: Guillain-Barré syndrome, acute ascending Landry's palsy; includes axonal variants

Epidemiology

According to aggregated data from 2024, the global incidence of Guillain-Barré syndrome is approximately 1.1 cases per 100,000 person-years, but varies by region and age. Incidence increases with age, with men being affected somewhat more often than women. Surges can be observed during infectious outbreaks (e.g., Zika), as well as during seasonal gastrointestinal and respiratory infections. [8]

The distribution of subtypes varies by geography: the demyelinating variant predominates in Europe and North America, while motor axonal forms are more common in Asia and Latin America. These differences partly reflect the diversity of infectious exposures and microbiota, as well as access to diagnostics. [9]

The number of patients requiring intensive care is comparable across different health systems, but mortality and complication rates are higher in resource-limited countries due to late diagnosis and limited availability of immune therapy and respiratory support. This highlights the role of routing and early transfer to centers with experience in managing such patients. [10]

Isolated risk signals have been reported at the pharmacovigilance level with some vaccinations (e.g., adenovirus vaccines for SARS-CoV-2, respiratory syncytial virus in the elderly), but the absolute risk is low and lower than the risk of Guillain-Barré syndrome after the infections themselves; national regulators emphasize that the benefits of vaccination outweigh the potential risks. [11]

Table 2. Key epidemiological landmarks

Indicator	Grade
Global incidence	~1.12 per 100,000 person-years
Sexual imbalance	Men more often
Peak age	Older age groups
Proportion of those requiring ventilation	~20-30% in the acute period
Geography of subtypes	Demyelinating - Europe/North America; axonal - Asia/Latin America

Reasons

In two-thirds of cases, infection is noted 1-4 weeks before onset. The most convincing link is with the intestinal infection Campylobacter jejuni, and less commonly with cytomegalovirus, Epstein-Barr virus, Mycoplasma pneumoniae, influenza viruses, and Zika. There is no direct "neurotropic" nerve destruction: the decisive role is played by the cross-reactivity of antibodies to bacterial components with nerve gangliosides. [12]

Campylobacter jejuni particularly often precedes motor axonal forms; these patients are more likely to have antibodies to GM1 and GD1a, which is associated with more rapid progression and severe weakness. This is important for understanding the variability of the disease course and the choice of respiratory function monitoring tactics. [13]

Viral epidemics provide a natural "stress test" for the system: with Zika, an excess risk of Guillain-Barré syndrome was observed, while with coronavirus infection, the connection was less clear and weaker than feared at the beginning of 2020. The overall conclusion is that infections remain the main trigger, and adverse outcomes are more often associated with them. [14]

There are rare associations with surgery and trauma, as well as with pregnancy and the postpartum period, but direct causal mechanisms for these scenarios are fewer than with infections. In each such case, the role of the trigger is assessed individually. [15]

Risk factors

Risk factors include older age, male gender, and a history of diarrhea or respiratory infection. Several cohorts have shown that low albumin levels on admission correlate with more severe disease and the need for ventilation, likely reflecting a systemic inflammatory response and nutritional status. [16]

The geographic distribution of subtypes can also be considered a "population" risk factor: in regions with high Campylobacter jejuni circulation, axonal forms and more severe disease progression are more common. This influences the organization of care: in such regions, it is advisable to conduct earlier and more frequent monitoring of respiration and autonomic functions. [17]

The presence of antibodies to gangliosides can simultaneously serve as a marker of the mechanism and an indirect predictor of outcome. High and persistent titers of GM1 antibodies are associated with poorer recovery; antibodies to GQ1b almost "sign" the Miller-Fisher phenotype, helping to speed up diagnosis. [18]

Despite isolated signals after some vaccines in the elderly, age-specific pharmacovigilance analyses show an extremely low absolute risk of Guillain-Barré syndrome after vaccination and no excess risk after mRNA vaccines; the main prevention is infection prevention. [19]

Pathogenesis

The immune response is triggered by molecular mimicry: antibodies targeting bacterial lipo-oligosaccharides recognize peripheral nerve gangliosides. This leads to complement activation at the nodes of Ranvier and damage to myelin or axolemma. In demyelinating variants, macrophage-mediated demyelination and conduction block predominate, while in axonal variants, direct axonal damage with flaccid paralysis predominates. [20]

At the phenotype level, the antibody "signature" is considered to be IgG to GM1 in motor axonal forms and IgG to GQ1b in Miller-Fisher syndrome and related conditions (including Bickerstaff brainstem encephalitis). These antibodies are not required for diagnosis but are useful for stratification. [21]

Autonomic dysfunction is explained by damage to the fine fibers, ganglia, and peripheral autonomic nerves, manifested by blood pressure instability, arrhythmia, intestinal atony, and urinary retention. These manifestations are common and require protocol monitoring. [22]

In the late stages of inflammation, a "secondary" component of pain may occur due to central sensitization. This explains why, in a significant proportion of patients, pain persists for months and years and requires a separate treatment program. [23]

Symptoms

Classically, the disease begins with paresthesia in the feet, followed by increasing symmetrical weakness of the legs, later the arms, and decreased or absent tendon reflexes. Within days, difficulty walking and climbing stairs may develop, and bilateral peripheral facial paresis, dysarthria, and dysphagia develop. Any asymmetry, persistent focal symptoms, or pyramidal signs suggest another diagnosis. [24]

Respiratory failure develops in 20-30% of patients due to weakness of the diaphragm and intercostal muscles. Shortness of breath at rest, inability to count to 20 on a single breath, and paradoxical breathing are late, ominous signs; early monitoring of vital capacity and forced inspiratory capacity is necessary. [25]

Pain is an under-recognized but common symptom: in many, it precedes weakness and is radicular, interscapular, or lumbar in nature; neuropathic pain in the feet is common. This requires an early analgesic strategy, otherwise sleep, mobilization, and rehabilitation are impaired. [26]

Autonomic dysfunction includes pulse and blood pressure lability, arrhythmias, intestinal atony, and urinary retention; severe dysautonomia increases the risk of arrhythmias and sudden death, so monitoring protocols are vital even in non-intensive care units.[27]

Classification, forms and stages

Based on the mechanism of damage, a distinction is made between the acute inflammatory demyelinating variant and axonal variants—acute motor and motor-sensory axonal neuropathies. There are phenotypic variants: Miller-Fisher syndrome (ophthalmoplegia, ataxia, areflexia), the pharyngeal-cervico-brachial form, and overlapping syndromes. [28]

The staged nature of the disease is typical: an increase phase (usually up to 2 weeks, maximum up to 4 weeks), a plateau (days to weeks), and recovery (weeks to months). Progression over 8 weeks suggests chronic inflammatory demyelinating polyneuropathy. [29]

The regional distribution of subtypes reflects triggers: the demyelinating variant predominates in Europe and North America; motor axonal variants are more common in Asia and Latin America. These differences are also partially reflected in electrophysiology. [30]

The "spectrum of antibodies to GQ1b" is considered separately: this includes Miller-Fisher syndrome and related conditions with ophthalmoplegia; they are characterized by a serological signature and, as a rule, a more favorable prognosis. [31]

Table 3. Main clinical variants and markers

Option	Key Features	The most characteristic antibodies	Comments
Acute inflammatory demyelinating	Symmetrical weakness, areflexia, demyelinating conduction block	There are no mandatory	More common in Europe/North America
Acute motor axonal	Pure motor weakness, rapid progression	GM1, GD1a	Often after Campylobacter jejuni
Acute motor-sensory axonal	Severe weakness and sensory disturbances	GM1 and others	More severe course
Miller-Fisher syndrome	Ophthalmoplegia, ataxia, areflexia	GQ1b	Often quickly confirmed serologically

Complications and consequences

Respiratory failure is the most dangerous complication; about a quarter of patients require mechanical ventilation, and pneumonia and sepsis are the leading causes of death in critically ill patients. Early risk assessment and transfer to a unit with respiratory support are critical. [32]

Autonomic dysfunction is common and manifests as pressure and rhythm lability, arrhythmias, intestinal obstruction, and urinary retention; these disorders increase the duration of hospitalization and the risk of fatal complications, requiring standardized monitoring and correction algorithms. [33]

Pain and fatigue can persist for months and years after discharge, impairing quality of life; a multidisciplinary rehabilitation program is required with an emphasis on pain control, restoration of endurance, and psychological support. [34]

Approximately 20% of patients remain limited in walking without support after 6 months; prognosis is influenced by age, rate of progression, subtype, and initial severity. The mEGOS and EGRIS indices help individualize the prognosis and treatment plan. [35]

When to see a doctor

Immediately - if progressive weakness in the legs or arms occurs, especially if it is symmetrical and accompanied by numbness or back pain. Urgently - if shortness of breath, difficulty swallowing, severe weakness of facial expressions, or voice disturbances occur. This may indicate involvement of the respiratory and bulbar muscles. [36]

Signs of danger include difficulty breathing while lying down, inability to pronounce a long sentence on a single breath, paradoxical breathing, bouts of tachycardia, or sudden changes in blood pressure. These signs require assessment of vital capacity, forced inspiratory capacity, and oxygen saturation. [37]

If symptoms appear after a recent bout of diarrhea or a cold, the likelihood of Guillain-Barré syndrome is higher. Don't wait for it to "go away on its own": the sooner specific therapy is started, the better the chances of avoiding ventilation and shortening the recovery time. [38]

In patients with ophthalmoplegia, gait unsteadiness, and loss of reflexes in the setting of a recent infection, Miller Fisher syndrome should be suspected and serologic testing for antibodies to GQ1b should be performed to expedite confirmation of the diagnosis.[39]

Diagnostics

Step 1. Clinical examination and neurological examination. They look for progressive symmetrical weakness, areflexia, sensory symptoms, bulbar and facial paresis, and autonomic dysfunction. Respiration is also assessed, measuring vital capacity and forced inspiratory capacity. [40]

Step 2. Cerebrospinal fluid (CSF) ("albumin-cytologic dissociation"). After 1 week from onset, most patients experience elevated protein levels with normal (or slightly elevated) cell counts. Pleocytosis of more than 50 cells per microliter prompts the search for alternatives (central nervous system infection, inflammatory neuropathy, etc.). Normal protein levels in the first week do not rule out diagnosis. [41]

Step 3. Electroneuromyography and nerve conduction studies. Reveals conduction blocks and slowing in the demyelinating form, or axonal signs in motor forms. During the first few days, the test may still be "insufficiently informative," so it is repeated after 1-2 weeks if the clinical suspicion is high. [42]

Step 4. Serology for ganglioside antibodies. Not required for everyone, but useful for subtyping: antibodies to GM1 support axonal motor forms; antibodies to GQ1b support Miller-Fisher syndrome and related phenotypes. The presence of such antibodies helps predict the course and confirm the diagnosis in atypical patients. [43]

Table 4. Diagnostic tests and characteristic findings

Method	What are we looking for?	Expected results	Comments
Lumbar puncture	Protein, cells	High protein with normal cell count; >50 cells/µL - seek an alternative	Sensitivity increases after 7 days
Electroneuromyography	Conductivity	Blocks and slowing (demyelination) or axonal signs	Repeated testing increases sensitivity
Antibodies to gangliosides	GM1, GQ1b, etc.	GM1 - motor axonal forms; GQ1b - Miller-Fisher	Useful for subtyping
Imaging (if indicated)	Exclusion of mimics	MRI of the roots with contrast may show enhancement	It is applied selectively.

Differential diagnosis

Guillain-Barré syndrome must be distinguished from spinal cord lesions (myelopathies), acute myopathies, neuromuscular transmission disorders, and toxic-metabolic polyneuropathies. The key is a thorough neurological "geography" of symptoms, cerebrospinal fluid (CSF), and electrophysiology. If in doubt, an MRI of the spinal cord is performed to detect compression. [44]

In myasthenia, the oculomotor and bulbar muscles rapidly fatigue, but reflexes are preserved, sensitivity is not impaired, and electrophysiology and pharmacological tests indicate a transmission failure at the neuromuscular junction. In spinal lesions, there are conductive sensory levels and pyramidal signs. [45]

Toxic and metabolic neuropathies (alcohol, vitamin deficiency, diabetes) are often chronic, with "sock-glove"-type sensory disturbances and without rapid ascending paralysis. If an infectious process of the central nervous system is suspected, the cerebrospinal fluid shows marked pleocytosis—this distinguishes it from Guillain-Barré syndrome. [46]

Miller-Fisher syndrome is sometimes confused with a vascular or inflammatory brainstem lesion; areflexia, the absence of focal central symptoms, and the presence of antibodies to GQ1b support a peripheral origin. [47]

Table 5. Quick reference points for differential diagnosis

State	Reflexes	Sensitivity	Liquor	Electrophysiology
Guillain-Barre syndrome	Reduced/absent	Often violated	Protein ↑, cells are normal	Demyelination or axonal pattern
Myasthenia gravis	Saved	Saved	Norm	Neuromuscular transmission defect
Acute myopathies	Moderately reduced	Saved	Norm	Myopathic pattern
Myelopathy	Increased	Conductor levels	Often the norm	MRI of the spinal cord - pathology
CNS infection	Different	Often central signs	Cells↑↑	According to the CNS clinic

Treatment

The primary goal is to ensure a safe environment: monitoring respiration (serial measurements of vital capacity and forced inspiratory capacity), oxygen saturation, pulse, and blood pressure, as well as early transfer to the intensive care unit if signs of worsening respiratory or bulbar failure occur. We're talking about hours, not days: being late means complicating the path to recovery. [48]

Two immune therapies have proven effective and are considered equivalent in clinical effect: intravenous immunoglobulin (IVIG) and plasmapheresis. IVIG is administered at a dose of 0.4 g per kilogram of body weight per day for 5 days; plasmapheresis is administered as a course of 4-5 treatments over 7-14 days. The choice depends on availability, contraindications, and logistics; sequential use of both treatments generally provides no additional benefit. [49]

Glucocorticosteroids alone do not improve outcomes in Guillain-Barré syndrome and are not recommended as standard therapy; the addition of methylprednisolone to intravenous immunoglobulin has not shown consistent clinical benefit. This is a key differentiator from chronic inflammatory demyelinating polyneuropathy. [50]

What should be done in severe cases and an "insufficient response" to first-line therapy? Current guidelines indicate that repeat courses of intravenous immunoglobulin do not improve outcomes by default and are associated with a high incidence of serious adverse events (including thrombosis). The decision to use "rescue" therapy should be made with extreme caution, preferably in a clinical trial setting or with strict indications. [51]

Innovative approaches (complement C5 inhibitors, neonatal immunoglobulin Fc receptor inhibitors, immunoglobulin cleavage enzymes) are being actively studied. To date, large complement inhibitor studies have not demonstrated convincing clinical benefit in addition to standard therapy, and data on Fc receptor inhibitors and enzymes remain preliminary. Their use outside of clinical trials has not become standard. [52]

Supportive care is multifaceted. It includes thrombosis prophylaxis in patients with limited mobility, skin care and pressure ulcer prevention, early nutritional support, a pain management protocol with an emphasis on neuropathic pain (first-line drugs include gabapentinoids, tricyclic antidepressants, and duloxetine; if necessary, short courses of opioids under strict supervision), as well as constipation prevention and treatment of urinary retention. [53]

Management of autonomic dysfunction requires regular monitoring of blood pressure and pulse, preparedness to treat brady- and tachyarrhythmias, careful fluid therapy to correct hypotension, and the use of vasopressors when indicated. Excessive stimulation, pain, and hypoxia can trigger "autonomic storms," so the environment should be calm, minimizing procedural pain. [54]

Respiratory support ranges from noninvasive methods to early intubation with controlled ventilation when vital capacity falls below critical thresholds or signs of respiratory muscle fatigue appear. Whenever possible, respiratory rehabilitation (inspiratory muscle training) is introduced during safe windows between procedures. [55]

Early rehabilitation is one of the best investments in outcome. Gentle active and passive movements, positioning, contracture prevention, vertical support, and progressive strength and functional training are used as safely as possible. For some patients, ankle orthoses are recommended while plantar extension is being restored. [56]

Patient and family education, as well as psychological support, reduce anxiety and depression and increase adherence to rehabilitation and pain management. A team model (neurologist, intensive care specialist, physical therapist, occupational therapist, speech therapist, nutritionist, psychologist, and nurse) improves outcomes and reduces the time to independent walking. [57]

Table 6. First-line immune therapies: key parameters

Therapy	Scheme	Effect	Special Notes
Intravenous immunoglobulin	0.4 g/kg/day for 5 days	Reduces recovery time and reduces the risk of ventilation	A repeat course is not routinely indicated.
Plasmapheresis	4-5 procedures in 7-14 days	The effect is comparable to immunoglobulin	Requires vascular access and resources
Glucocorticosteroids	Not recommended	Do not improve outcomes	Possible as treatment for concomitant conditions
Experimental means	Different	There is not enough data yet	Only for research purposes

Prevention

There is no specific “vaccine against Guillain-Barré syndrome”; prevention is primarily about preventing infections and their complications: hand and food hygiene (especially to reduce the risk of Campylobacter jejuni), timely vaccination against seasonal respiratory infections according to national calendars, and reasonable behavior during epidemic periods. [58]

In the context of vaccination, regulatory data should be relied upon: no excess risk of Guillain-Barré syndrome has been detected for mRNA vaccines against coronavirus infection; rare signals have been recorded for individual vaccines in the elderly group, but the absolute risk is low, and the benefit from preventing severe infections is significantly higher. The decision is made in consultation with a physician. [59]

Preventing complications in those already ill is no less important through "in-hospital prophylaxis": anticoagulation, skin care, proper nutritional support, pain management protocols, and prevention of respiratory and urinary tract infections. This reduces mortality and improves recovery. [60]

For families and caregivers, the key is training in safe mobilization, the use of orthoses and mobility aids, and recognizing "red flags" of symptom recurrence. This minimizes the risk of injury and decompensation at home. [61]

Forecast

Most patients return to independent walking within 6 months, but 20-30% have persistent deficits; a single percent have severe residual impairments. Advanced age, rapid onset and severe weakness at peak, axonal variants, and severe dysautonomia contribute to a worse prognosis. [62]

Clinical scales are used for individual prognosis. The modified Erasmus Outcome Scale assesses the risk of inability to walk independently at 4 and 26 weeks based on age, strength, and previous diarrhea; the modified respiratory failure scale predicts the need for ventilation in the next week. These tools have also been validated in international cohorts. [63]

Early specific therapy and team-based rehabilitation improve outcomes. Even in severe cases, lasting recovery is possible, but it requires time, consistency, and adequate pain and fatigue support. [64]

Even with good functional recovery, some patients report chronic fatigue, pain syndromes, and anxiety-depressive symptoms, which require continued observation and, if necessary, psychotherapeutic and drug treatment. [65]

Table 7. Prognostic tools

Tool	What does it predict?	Input parameters	Who is it useful for?
Modified Erasmus Outcome Scale (mEGOS)	Unsupported walking at 4 and 26 weeks	Age, MRS-sum of strength, previous diarrhea	To all hospitalized
Modified EEGRIS (mEGRIS)	Risk of ventilation in the coming week	Clinical presentation and simple indicators	In the first days of illness

FAQ

Is it contagious? No. The syndrome is the body's immune response to a previous infection, but is not "contagious" in itself. [66]

Is it possible to treat the patient with painkillers alone and wait? No. Urgent evaluation and first-line immune therapy are needed; delay increases the risk of ventilation and disability. [67]

Which to choose: immunoglobulin or plasmapheresis? Both methods are effective; the choice depends on availability, contraindications, and logistics. Sequential use does not provide proven additional benefit. [68]

Should I repeat the immunoglobulin course if recovery is poor? Routinely, no: controlled studies have shown no benefit, but have identified more serious adverse events. The decision is strictly individual. [69]

Are there any "new drugs"? Complement inhibitors, Fc receptor inhibitors, and immunoglobulin-degrading enzymes are being tested; these are not yet standard and are used in research settings. [70]

Appendix: Map of triggers and antibodies

Table 8. Triggers, antibodies and clinical associations

Trigger	The most typical antibodies	More commonly associated variant	Clinical notes
Campylobacter jejuni	GM1, GD1a	Motor axonal	Rapid increase in weakness
Cytomegalovirus	Different	Demyelinating	Frequent pain and tenderness symptoms
Epstein-Barr virus	Different	Demyelinating	In young adults
GQ1b "Spectrum" (often without an obvious trigger)	GQ1b	Miller-Fisher syndrome	Ophthalmoplegia and ataxia